Repare Therapeutics’ (RPTX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Repare Therapeutics (NASDAQ:RPTX) in a research note released on Monday morning, Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

Separately, Lifesci Capital upgraded shares of Repare Therapeutics to a strong-buy rating in a report on Monday, July 29th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Repare Therapeutics presently has a consensus rating of Buy and an average target price of $17.33.

Repare Therapeutics Stock Performance

Shares of RPTX stock opened at $3.38 on Monday. The firm’s 50 day moving average price is $3.26 and its 200-day moving average price is $3.61. Repare Therapeutics has a one year low of $2.71 and a one year high of $13.17. The firm has a market cap of $143.46 million, a P/E ratio of -3.07 and a beta of 0.71.

Repare Therapeutics (NASDAQ:RPTX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.03. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%. The firm had revenue of $1.07 million for the quarter, compared to analyst estimates of $4.02 million. As a group, research analysts predict that Repare Therapeutics will post -2.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Repare Therapeutics

A number of hedge funds have recently added to or reduced their stakes in RPTX. XTX Topco Ltd acquired a new stake in Repare Therapeutics during the 2nd quarter worth approximately $110,000. Marshall Wace LLP acquired a new stake in shares of Repare Therapeutics in the 2nd quarter valued at $273,000. Jump Financial LLC acquired a new stake in shares of Repare Therapeutics in the 4th quarter valued at $289,000. Opaleye Management Inc. acquired a new stake in shares of Repare Therapeutics in the 1st quarter valued at $318,000. Finally, Bank of Montreal Can raised its holdings in shares of Repare Therapeutics by 5.4% in the 2nd quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock valued at $366,000 after purchasing an additional 5,673 shares in the last quarter. 85.09% of the stock is currently owned by institutional investors and hedge funds.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.